Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 3/20 | 0.33 |
| ▸ | TACR3 | P29371 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14118644 | 0.89 | AKT1 (0.42) | ALDH1A1KDM4ELMNAHPGDHSD17B10 | |
| SCHEMBL1901743 | 0.83 | PDE2A (0.35) | SCN9APDE2ATACR3SSTR4ADORA2B | |
| SCHEMBL14120192 | 0.83 | CHEK1 (0.37) | ALDH1A1HPGDHSD17B10SCN9APDE2A | |
| SCHEMBL12677205 | 0.83 | AKT1 (0.43) | — | |
| SCHEMBL1907804 | 0.81 | PDE2A (0.34) | ALDH1A1SCN9AITGB1ITGA4ITGB7 | |
| SCHEMBL1902450 | 0.81 | ALDH1A1 (0.35) | ALDH1A1KDM4ELMNAHPGDHSD17B10 | |
| SCHEMBL1904734 | 0.81 | ALDH1A1 (0.36) | ALDH1A1HPGDHSD17B10SCN9APDE2A | |
| SCHEMBL1904033 | 0.80 | AURKA (0.37) | ALDH1A1KDM4EHPGDHSD17B10PDE2A | |
| SCHEMBL14118880 | 0.80 | SCN9A (0.36) | ALDH1A1HPGDHSD17B10SCN9APDE2A | |
| SCHEMBL1902096 | 0.80 | PTPN11 (0.39) | ALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | ALDH1A1 4803/4885KDM4E 2856/4885LMNA 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.